Zithromax Injection Articles
InSite's AzaSite cleared in Canada for pink eye
2 April 2009
Four Novartis drugs and B-MS
9 March 2009
US FDA guidance for old antibiotic patents
15 December 2008
UK's RPS publishes azithromycin guidance
17 November 2008
APP Puerto Rico heparin facility cleared by FDA
1 September 2008
SFDA approves Tianyin's azithromycin
24 March 2008
US Pres promises $350M for neglected diseases
3 March 2008
US Pres promises $350M for neglected diseases
3 March 2008
Inspire/InSite's AzaSite debuts in the USA
20 August 2007
Inspire to sell $75M of stock
30 July 2007
Pliva to pay damages in inventorship suit
18 June 2007
$8.9M neglected tropical disease research boost
19 March 2007
$8.9M neglected tropical disease research boost
19 March 2007
InSite and Inspire in ocular antibiotic deal
26 February 2007
Pliva gets US OK for generic Zithromax
29 January 2007
French antibiotics consumption falls
8 January 2007
Pfizer and Teva resolve two law suits
27 November 2006
More US firms push cheap drugs on workers
13 November 2006
Pliva swings to $33M profit in 2nd-qtr 2006
18 September 2006
Canada: branded drugs slip, generics grow
27 March 2006
Pfizer takes action against Teva and Sandoz over azithromycin
20 February 2006
GSK buys Pliva Research Inst for $50M
20 February 2006
APP gains FDA appro for azithromycin injectable
19 December 2005
Pfizer acquires privately-held Bioren
22 August 2005
FDA clears Pfizer's single-dose Zmax
20 June 2005
InSite enters AzaSite supply deal
23 May 2005
Bentley to sell generic azithromycin in Spain
9 August 2004
Pfizer $6M settlement over Zithromax ads
13 January 2003
Pliva to acquire Sidmak for $153M
17 June 2002
Zithromax gets US OK for COPD infections
3 June 2002
Zithromax "no efficacy in acute bronchitis"
20 May 2002
Zithromax disappoints in heart disease trials
25 March 2002
Zithromax approved by FDA for new otitis media regimen
7 January 2002
Zithromax approved by FDA for new otitis media regimen
18 December 2001
Pfizer's one-day Zithromax course squeaks through FDA advisory panel
12 November 2001
FDA backs new Zithromax regimen for acute otitis media
8 November 2001
Update - Pfizer second-quarter net income leaps 31%
18 July 2001
Pfizer 1st-qtr 2001 net income rises 34%
23 April 2001
Chinese pharma sales, other industry data
6 February 2001
Stock Commentary Tokyo
31 August 2000
Slight slip in Tokyo pharma stocks
22 August 2000
Pfizer leads 1st-qtr US physician detailing
11 July 2000
South Africa, Pfizer ponder Diflucan offer
30 June 2000
Bayer's Avelox versus Zithromax in ABECB
11 May 2000
Pliva 1999 net profits show strong rise
3 April 2000
Pfizer EPS in 4th qtr rises 56%
18 January 2000
Pfizer Aims For Top Slot After Millenium
10 November 1998
Orchid Building New Drug Plant in India
9 November 1998
US Majors Post Strong Earnings For 3rd Quarter
15 October 1998
Pliva Results Earn CSFB Upgrade
1 October 1998
"Extraordinary"Viagra Sales Lift Pfizer Earnings
10 July 1998
USA's Most-Dispensed Rx Drugs In April 1998
20 May 1998
ACADEMIC Casts Doubt On Chlamydia Hypothesis
20 April 1998
Pfizer Posts Double-Digit Sales & Earnings Growth
15 April 1998
Pfizer Espana Sales Climb 19%
24 March 1998
Biaxin As Effective As Co-Amoxiclav In Bronchitis
11 February 1998
Greece To Slim Official Drug List
4 February 1998
Max-GB To Double Penicillin Output
4 December 1997
Drug Promo Meetings "Up 61% Since 1995"
27 October 1997
Croatia's Pliva Set To Challenge Central European Powerhouses
26 September 1997
ROXIS - More Support For Antibiotics In Heart Disease
13 August 1997
Pfizer Enters New Product Cycle With Strong Potential
7 August 1997
Pfizer's Good Volume Growth Marred By Strong $
17 July 1997
Antibiotics May Offer New Therapeutic Option In MI
16 July 1997
Croatia's Pliva Plans Expansion
11 July 1997
Pfizer Gets AAA Ranking From S&P
12 June 1997
Forex Impacts Sales At Pfizer, Merck And S-P
22 April 1997
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
